Leo Pharma executive on EU progress: This is a huge milestone for us

Now that the CHMP has recommended approval for the eczema drug Adtralza, Leo Pharma can start preparing for the firm's most significant launch in years.

Leo Pharma Corporate EVP and Head of Global R&D Jörg Möller | Photo: Leo Pharma / PR

On Friday, Leo Pharma received an approval recommendation for the drug tralokinumab, which will be known as Adtralza onwards, for treating eczema. This is the culmination of five years' hard work, and for the the Danish dermatology company, it is the first time it has full control of a global launch relating to one of its biological drugs.

For this reason, Leo Pharma Corporate Executive Vice President and Head of Global Research & Development Jörg Möller is happy to discuss the importance of this announcement from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs